<\/p>\n
Rtqs 200<\/strong> bevat hydroxychloroquine sulfate<\/strong> 200 mg (RPG Life Sciences). It treats and prevents chloroquine-sensitive malaria<\/strong>, and is the first-line aminoquinoline for rheumatoid arthritis<\/strong>, systemic lupus erythematosus<\/strong>, discoid lupus<\/strong>, en Sj\u00f6gren’s syndrome<\/strong>. Dose: 400 mg\/day for autoimmune disease (long-term maintenance \u2264 5 mg\/kg\/day actual body weight); 800 mg loading then 400 mg at 6 \/ 24 \/ 48 h for acute uncomplicated chloroquine-sensitive malaria. Mandatory baseline + annual ophthalmology screening<\/strong> after 5 years of continuous use to detect retinopathy. Modern endemic areas (sub-Saharan Africa, India, Southeast Asia, Amazon) have widespread chloroquine resistance \u2014 hydroxychloroquine is NOT the right prophylaxis for those destinations. Take with food to reduce GI upset.<\/p>\n<\/div>\n \ud83d\udee1\ufe0f Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days we ship a free replacement on EMS or ITPS courier.<\/p>\n Rtqs 200 is sourced from a WHO-GMP certified manufacturer and shipped worldwide in discreet packaging. Every order is backed by our Reshipment Assurance Policy<\/a> and supported by our 1.400+ klantbeoordelingen<\/a>. Worldwide shipping with no prescription paperwork.<\/p>\n Rtqs 200 is a 200 mg hydroxychloroquine sulfate tablet manufactured by RPG Life Sciences under WHO-GMP certified conditions. Hydroxychloroquine is a 4-aminoquinoline antimalarial that doubles as the workhorse conventional synthetic disease-modifying anti-rheumatic drug (csDMARD)<\/strong> for mild-to-moderate rheumatoid arthritis and connective-tissue disease, with the lowest toxicity profile of any DMARD when dosed correctly.<\/p>\n Hydroxychloroquine accumulates in the acidic lysosomes of cells. In malaria parasites<\/strong> it interferes with haemoglobin digestion in the food vacuole, allowing toxic free haem to accumulate and kill the parasite. In autoimmune disease<\/strong> the lysosomotropic effect raises lysosomal pH, which interferes with antigen processing by dendritic cells, dampens Toll-like receptor signalling (especially TLR-7 and TLR-9 which recognise self-nucleic acids), and reduces interferon-\u03b1 production. The dual mechanism explains why a single drug treats two unrelated diseases.<\/p>\n Half-life is ~ 40 days (steady state 4\u20136 weeks). Effect on autoimmune disease takes 8\u201312 weeks to develop and continues to deepen over 6 months \u2014 patience and adherence matter.<\/p>\nWaarom bestellen bij MedsBase<\/h3>\n
About Rtqs 200<\/h2>\n
How hydroxychloroquine works<\/h2>\n
Indicaties en dosering<\/h2>\n